Login / Signup

Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters.

Takayuki KatsubeYuji InoueTakahiro FukuharaTakeshi KanoToshihiro Wajima
Published in: European journal of clinical pharmacology (2020)
In consideration with in vitro data, the in vivo and in silico results suggested no clinically significant DDI potential of lusutrombopag with other medical products via metabolic enzymes and transporters.
Keyphrases
  • healthcare
  • molecular docking
  • electronic health record
  • big data
  • risk assessment
  • machine learning
  • deep learning